LUCY

Competitive advantage analysis · healthcare

Medical Devices & Diagnostics
Overall moat score
35/100
Developing

About

Lucyd, Inc engages in the development and sale of smart eyeglasses and sunglasses in North America. Its flagship product is the Lucyd Lyte which enable the wearer to listen to music, take and make calls, and use voice assistants and ChatGPT to perform various smartphone tasks hands-free. It also provides Nautica Powered by Lucyd smart eyewear collection and various branded … Full LUCY analysis →

Competitive advantage assessment

Key strengths

  • Improving FCF Trend FCF trend score is positive (score 0.93). Improving FCF margin signals compounding operational leverage.
  • Expanding Operating Margin Operating margin trend is positive (score 0.94). Margin expansion confirms commercial leverage is building.

Key risks

  • Below-Peer Gross Margins Gross margin quality lags peers (score 0.15). May indicate commodity-like product mix or distributor margin drag.
  • Weak Capital Return Profile Capital return quality is below peers (score 0.20). Low ROIC raises questions about M&A discipline and pipeline ROI.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power & Consumable Moat

Weak
16

Where LUCY ranks in Medical Instruments & Supplies

ranks #45 of 62 scored companies in Medical Instruments & Supplies by moat score — the top 73%. The widest moat in the group is Intuitive Surgical, Inc. (ISRG) at 86/100.

Moat scores for companies ranked near LUCY in Medical Instruments & Supplies
# Company Moat score Rating
41 JIN MEDICAL INTERNATIONAL LTD. ZJYL 39/100 Developing
42 NexGel, Inc NXGL 38/100 Developing
43 NexGel, Inc Warrant NXGLW 38/100 Developing
44 Harvard Bioscience, Inc. HBIO 37/100 Developing
45 LUCY LUCY 35/100 Developing
46 Bionano Genomics, Inc. BNGO 35/100 Developing
47 Anteris Technologies Global Cor AVR 34/100 Developing
48 Stereotaxis, Inc. STXS 33/100 Developing
49 OraSure Technologies, Inc. OSUR 33/100 Developing

See every Medical Devices & Diagnostics company ranked by moat score →

How LUCY scores on the Medical Devices & Diagnostics defenses

Pricing Power & Consumable Moat

Score 16 · 25% of the moat score

In MedTech, pricing power is rarely about the machine — it is about what the machine consumes.

R&D Pipeline & Capital Returns

Score 14 · 20% of the moat score

Research spending is how a device company keeps its installed base current, but spending alone proves nothing.

FCF Quality & Cash Conversion

Score 52 · 20% of the moat score

MedTech companies grow by acquisition, and the resulting intangible amortisation depresses reported earnings without consuming any cash.

Commercial Execution

Score 49 · 15% of the moat score

Devices are sold into hospitals and labs through committees, tenders and long qualification cycles, which makes the sales organisation expensive and hard to replicate.

Capital Structure & Resilience

Score 48 · 12% of the moat score

Serial acquirers carry debt, and the question is whether the cash flows underneath it are dependable enough to service it through a downturn.

Growth Durability

Score 60 · 8% of the moat score

Growth durability separates an expanding installed base from a good product cycle.

How each Medical Devices & Diagnostics defense is measured, in full →

Understanding LUCY's moat

What is LUCY's moat score?

LUCY (LUCY) scores 35 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as developing. It ranks #45 of 62 scored companies in Medical Instruments & Supplies, the top 73%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 61 companies in Medical Instruments & Supplies. Its strongest defense is Growth Durability (60/100) and its weakest is R&D Pipeline & Capital Returns (14/100).

How does LUCY compare with other Medical Instruments & Supplies companies?

LUCY ranks #45 of 62 scored companies in Medical Instruments & Supplies by moat score. The widest moat in Medical Instruments & Supplies is Intuitive Surgical, Inc. (ISRG) at 86/100. The companies ranked closest are Harvard Bioscience, Inc. (HBIO) at 37 just above it and Bionano Genomics, Inc. (BNGO) at 35 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Medical Devices & Diagnostics in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 61 companies in Medical Instruments & Supplies. The defenses are then weighted to produce the overall score out of 100.

Why is LUCY scored with the Medical Devices & Diagnostics template?

Medical device and diagnostics companies place an instrument once and then sell the consumables, reagents and service that instrument needs for the next decade. The economics are a razor-and-blade model wrapped in regulatory approval and clinician habit, so the MedTech template scores the durability of that installed base rather than the size of any single product launch.

Which competitive defenses are measured for LUCY?

The Medical Devices & Diagnostics template measures 6 defenses, and LUCY scores: Pricing Power & Consumable Moat (16), R&D Pipeline & Capital Returns (14), FCF Quality & Cash Conversion (52), Commercial Execution (49), Capital Structure & Resilience (48), Growth Durability (60). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000